- Pandorum Technologies has entered a strategic collaboration with Nucelion Therapeutics to expand manufacturing of its exosome-based therapeutics across the APAC region.
- The partnership will support process scale-up, GMP production and quality control as Pandorum’s programmes move towards clinical trials.
Pandorum Technologies has announced a strategic collaboration with Nucelion Therapeutics, a Hyderabad-based contract research, development and manufacturing organisation (CRDMO), to strengthen manufacturing capabilities for its exosome-based therapeutic platform in the Asia-Pacific region. The collaboration is intended to support regional supply and regulatory readiness as Pandorum’s assets progress towards clinical trials.
Under the agreement, Nucelion Therapeutics will provide end-to-end contract manufacturing support, including process scale-up, GMP-compliant production and quality control of pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells. Nucelion is a wholly owned subsidiary of Bharat Biotech and focuses on advanced biologics manufacturing.
The companies stated that the collaboration aligns with Pandorum’s strategy to build regionally aligned manufacturing infrastructure to support clinical and future commercial milestones. The partnership also reflects India’s growing role in the development and manufacture of advanced biologic therapies for global markets.
“We are pleased to partner with Pandorum Technologies on the development of Kuragenx, an innovative exosome-based therapy with the potential to redefine the treatment paradigm for ocular diseases.”
Dr. Raghu Malapaka, PhD, CBO, Nucelion Therapeutics
Pandorum’s current programmes are focused on ocular surface injury and inflammatory corneal diseases, including Stevens–Johnson syndrome and neurotrophic keratitis. The company plans to expand its disease-modifying treatments to additional indications affecting the skin, pulmonary system and other organs impacted by inflammation, vascular pathologies and fibrosis.
“As our programmes advance toward clinical and commercial milestones, establishing robust, regionally aligned manufacturing infrastructure is a strategic priority.”
Dr Tuhin Bhowmick, Co-Founder and Chief Executive Officer of Pandorum Technologies
